Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPD-1 in Advanced Solid Tumors
NCT06944457Phase 1Recruiting
- Sponsor
- Pharosgen
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MPD-1 in solid tumor (advanced stage), sponsored by Pharosgen. Primary endpoints: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) Determination at 18 weeks, Incidence of Treatment-Related Adverse Events at 18 weeks and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
MPD-1
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06944457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06944457.